<DOC>
	<DOCNO>NCT01026142</DOCNO>
	<brief_summary>This randomize , two-arm study evaluate efficacy safety combination trastuzumab capecitabine without pertuzumab patient human epidermal growth factor receptor 2 ( HER2 ) -positive metastatic breast cancer . The study population consist female patient , whose disease progress follow previous trastuzumab therapy metastatic disease . All patient Arm A Arm B receive trastuzumab ( 8 mg/kg iv load dose 6 mg/kg iv every 3 week thereafter ) capecitabine oral twice daily 14 day every 3 week ( 1250 mg/m2 twice daily Arm A 1000 mg/m2 twice daily Arm B ) . In addition , patient Arm B receive pertuzumab ( 840 mg iv load dose 420 mg iv thereafter ) every 3 week . Study treatment continue disease progression unacceptable toxicity .</brief_summary>
	<brief_title>A Study Combination Trastuzumab Capecitabine With Without Pertuzumab Patients With HER2-positive Metastatic Breast Cancer ( PHEREXA )</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Pertuzumab</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Adult female patient &gt; /=18 year age Metastatic HER2 positive breast cancer Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Disease progression follow trastuzumabbased therapy 1st line metastatic breast cancer ( trastuzumab must part last prior treatment regimen ) Prior treatment taxanecontaining regimen Left ventricular ejection fraction ( LVEF ) &gt; /=50 percent For woman childbearing potential agreement use highly effective nonhormonal form contraception two effective form nonhormonal contraception patient and/or partner . Contraception must continue duration study treatment least 6 month last dose study drug treatment Prior treatment pertuzumab capecitabine Concurrent treatment experimental drug Concurrent immunotherapy anticancer hormonal therapy Serious concurrent disease ( e.g . active infection , uncontrolled hypertension , cardiovascular disease ) Central nervous system ( CNS ) metastases , well controlled History exposure anthracycline cumulative dose equivalent 360mg/m2 History congestive heart failure New York Heart Association criterion , serious cardiac arrhythmia require treatment History myocardial infarction within 6 month prior randomization History LVEF decline 50 % prior trastuzumab therapy cardiac toxicity previous trastuzumab treatment necessitated discontinuation trastuzumab History another cancer could affect compliance result interpretation Inadequate organ function Pregnant breastfeeding woman life expectancy &lt; 12 week</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>